#South Korea #Seongnam #Bridge Biotherapeutics #BBT-877 #fibrosis

Bridge Biotherapeutics to Present at the J.P. Morgan Healthcare Conference

Bridge Biotherapeutics, a leading clinical-stage biotech company from South Korea, is gearing up for a significant presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Scheduled for January 16, 2025, this event is a cornerstone for professionals in the healthcare sector, allowing companies like Bridge Biotherapeutics to showcase their innovations and forge essential partnerships.

The presentation will be led by James Jungkue Lee, the company's Founder and CEO. The event will take place in the Georgian Room at The Westin St. Francis in San Francisco, set for the morning session from 9:45 to 10:25 a.m. PST. During this time, Lee will discuss the company's latest advancements, particularly focusing on BBT-877, a promising candidate drug that targets idiopathic pulmonary fibrosis (IPF).

Strategic Partnerships and Future Outlook

In addition to the presentation, Bridge Biotherapeutics is keen on discussing potential business development opportunities with investors and partners. The company is actively exploring collaborations that can help propel the development of BBT-877 further. With top-line results from a Phase 2 study of BBT-877 expected in April 2025, the anticipation and relevance of this presentation will surely attract considerable interest.

About Bridge Biotherapeutics

Founded in 2015, Bridge Biotherapeutics operates with a mission to discover and develop groundbreaking therapeutics that address critical areas with high unmet medical needs, particularly in fibrotic diseases and various cancer types. The company is not only working on BBT-877 but is also advancing BBT-207, a targeted therapy designed to treat non-small cell lung cancer (NSCLC) with specific mutations.

As the conference approaches, stakeholders in the biotech community are eagerly awaiting insights from Bridge Biotherapeutics, hoping to gain a deeper understanding of its research trajectory and market strategy. For those interested in meeting with the Bridge team during the conference, arrangements can be made through their official communication channels.

In summary, Bridge Biotherapeutics' participation in the J.P. Morgan Healthcare Conference positions it as a notable player on the biotech stage, emphasizing its commitment to innovation in treatment for serious health conditions such as fibrosis and cancer. The upcoming discussions will not only highlight the potential of existing therapies but also pave the way for future breakthroughs that could have far-reaching implications in the healthcare landscape.